Approval · Notice of Compliance 23425 · 2020
ACT REPAGLINIDE: Notice of Compliance 23425
Issued April 6, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23425
- Date
- April 6, 2020
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Merger - buyout
- Canadian reference product
- GLUCONORM (Novo Nordisk Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT REPAGLINIDE | 02321475 | Dormant |
| ACT REPAGLINIDE | 02321483 | Dormant |
| ACT REPAGLINIDE | 02321491 | Dormant |
Medicinal ingredients
- REPAGLINIDE 0.5 MG per TAB
- REPAGLINIDE 1 MG per TAB
- REPAGLINIDE 2 MG per TAB